ESPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Esperion Therapeutics Inc (ESPR) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is experiencing a bearish trend, insider selling is significant, and financial performance shows mixed results with revenue growth but a sharp decline in net income and EPS. While analysts have raised the price target and maintain an Outperform rating, the lack of recent positive news or strong trading signals suggests holding off on investment until clearer positive catalysts emerge.
The technical indicators suggest a bearish trend. The MACD is negative and expanding downward, the RSI is neutral at 20.342, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a current price of $2.18, below S1 ($2.27) and approaching S2 ($2.098).
Gross margin improved to 83.46%, up 32.67% YoY.
Insiders are selling heavily, with a 2002.57% increase in selling over the last month. Net income dropped by -390.04% YoY, and EPS declined by -336.36% YoY. The stock has a 70% chance of declining -5.16% in the next week based on similar candlestick patterns.
In Q4 2025, revenue increased significantly to $168.45M, up 143.73% YoY. However, net income dropped to $61.83M, down -390.04% YoY, and EPS fell to $0.26, down -336.36% YoY. Gross margin improved to 83.46%, up 32.67% YoY.
Analysts from Citizens raised the price target to $5 from $4 and maintain an Outperform rating. They highlight the company's Vision 2040 plans, recent acquisition of Corstasis Therapeutics, and pipeline expansion through ESP-2001 as positive developments.
